Panobinostat (LBH589)

For research use only. Not for use in humans.

目录号:S1030 别名: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Phase 3。

规格 价格 库存 购买数量  
RMB 731.86 现货
RMB 2189.52 现货
RMB 5485.18 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Panobinostat (LBH589)发表文献216篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Panobinostat (LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Phase 3。
靶点
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
体外研究

LBH589诱导MOLT-4和Reh细胞凋亡,这种作用具有时间和剂量依赖性。而且,LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长,处理48小时,具有剂量依赖性。与对照组细胞相比,用LBH589处理的细胞,在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关,LBH589也降低c-Myc的表达水平,具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589(10 nM)处理Reh细胞,最初增强c-Myc的表达水平,之后一直降低c-Myc的表达水平。此外,LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下,LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。[1]此外, LBH589抑制非小细胞肺癌细胞系生长,如人类H1299,L55和A549,IC50分别为5,11和30 nM;间皮瘤细胞生长,如人类OK-6和 Ok-5,IC50分别为5和7 nM;及小细胞肺癌细胞系生长,如人类RG-1和LD-T,IC50分别为4和5 nM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCzeHdNOC1zMDFOwG0> M1;LOFAuPCCm M4PNcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{LGSVI3PzB{N{i0
HepG2 M4rOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT4SpQxNTFyIN88US=> MWqwMVQh\A>? MmXrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIP0T5AzPjdyMke4OC=>
HT29 MoTFSpVv[3Srb36gRZN{[Xl? M2qwPFUxyqCwTR?= Mn36NlQuPzJiaB?= NGeyTXZqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDR6wrDoxsA> NV\iT2ZjOjZ5MEK3PFQ>
HepG2 NFLQTHJHfW6ldHnvckBCe3OjeR?= MmjFOVDDqG6P MWmyOE04OiCq NIDvO3JqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDJ2wrDoxsA> MV:yOlcxOjd6NB?=
HCC827 NXL5RVdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D2e|UwPy53L{GwJI5O M3G2N|czyqCq NYnjVVQ4TE2VTx?= MV;lcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NUnuR3RLOjZ4N{W0PFQ>
A549  M4\TXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17telExNzF3L{KwJI5O Ml\OO|LDqGh? Ml7pSG1UVw>? MXHlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? MVKyOlY4PTR6NB?=
NCI-H460  M37IXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXV[HhVOTBxMkCvN|Ahdk1? MWG3NuKhcA>? MUTEUXNQ MlvF[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? MYGyOlY4PTR6NB?=
J89GFP M1\3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[wSG1UV8Li Mof1SWM2OD12OT64OUDDuSBzMj62OUBvVQ>? NX7DcWMzOjZ3NkO1Olg>
THP89GFP Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzzO|NFVVORwrC= MWLFR|UxRTF7LkO0JOKyKDZwNEOgcm0> NVvxcpFDOjZ3NkO1Olg>
SK-NEP-1 NYnaUohKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\UR|lnOC5yMfMAl|ExNjBizszN NW\mem1HOjRiaB?= M2\oOGROW00EoB?= M3PG[mlEPTB;N{[uN|Qhdk1? NFvy[Y0zPjF5NkKxPS=>
G401 MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKwMlAy6oDVMUCuNEDPxE1? NUjxdFZyOjRiaB?= NHLZUI5FVVORwrC= NYTJXmZ{UUN3ME2xOFMvODJibl2= MliwNlYyPzZ{MUm=
SK-NEP-1 NVvVOIQ3S2WubDDWbYFjcWyrdImgRZN{[Xl? MmjrOVAhdk1? NVqxR296OeLCk{Sg[C=> NE\MW3FFVVORwrC= MoK1doVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz NEHn[pYzPjF5NkKxPS=>
G401 NUHvSXJzS2WubDDWbYFjcWyrdImgRZN{[Xl? Mo\zOVAhdk1? NHzHNWky6oDVNDDk MXPEUXNQyqB? MknxdoVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz NInGZo4zPjF5NkKxPS=>
SK-NEP-1 M4fKXWFxd3C2b4Ppd{BCe3OjeR?= M4rzUVUxNzFyMDDuUS=> M3f1SVI1KGh? NVPRcVJxTE2VT9Mg M3fSZ4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGPxWWMzPjF5NkKxPS=>
G401 M1:yXWFxd3C2b4Ppd{BCe3OjeR?= NY\yTFd1PTBxMUCwJI5O NWLyR5ZMOjRiaB?= NVHRVFBETE2VT9Mg NELWUVRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXWyOlE4PjJzOR?=
SK-NEP-1 NH\Gd3FHfW6ldHnvckBCe3OjeR?= MYK1NE8yODBibl2= NXLWSolGOjRiaB?= MVHEUXNQyqB? M1LaSpNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? NFjvV40zPjF5NkKxPS=>
G401 MnvtSpVv[3Srb36gRZN{[Xl? MVW1NE8yODBibl2= NFnkT5MzPCCq NYXwSZRPTE2VT9Mg Ml3Pd4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? M4fEdFI3OTd4MkG5
SK-NEP-1 NXzGc2Q3TnWwY4Tpc44hSXO|YYm= NIG0ZpE2OC9zMECgcm0> NF\oR4gzPCCq M1S5WGROW00EoB?= NHLXdm9qdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? MkDrNlYyPzZ{MUm=
G401 NXeyZYNVTnWwY4Tpc44hSXO|YYm= MUC1NE8yODBibl2= MX[yOEBp MXLEUXNQyqB? M3jBTolv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh MYKyOlE4PjJzOR?=
RPMI 8226 MmXYR4VtdCCVdYL2bZZidCCDc4PhfS=> MXKyM|QwPiCwTR?= NHf0Wok1QOLCiXi= MUnpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp NHjWWlIzPjByMEK5Ni=>
OPM2 NYDL[VIzS2WubDDTeZJ3cX[jbDDBd5NigQ>? MVuyM|QwPiCwTR?= M3Wwe|Q56oDLaB?= NXuzVVZZcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= MUCyOlAxODJ7Mh?=
U266 M3HG[2NmdGxiU4Xyeol3[WxiQYPzZZk> NHLTXXozNzRxNjDuUS=> Mk\lOFjjiImq MX;pcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp MnvPNlYxODB{OUK=
H929 MmXTR4VtdCCVdYL2bZZidCCDc4PhfS=> NWLBO4NTOi92L{[gcm0> NXXYU4ZyPDkkgJno NHnXdZpqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq M{HoWlI3ODByMkmy
RPMI 8226  NULIR4hQSXCxcITvd4l{KEG|c3H5 M4HrVVTjiImwTR?= M3f4c|I1NzR6IHi= NG\y[XJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NYjwbXNWOjZyMECyPVI>
HCC827 NGjCfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxNEBvVQ>? MnzaOFghcA>? NYmwVmhHTE2VTx?= NFvuXI1mdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= NFXRbVkzPTl2NE[xOy=>
NCI-H23 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexNEBvVQ>? MYe0PEBp NX;LbZBCTE2VTx?= NVfKcHhY\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= MkW0NlU6PDR4MUe=
AML3 NYPFWmxWTnWwY4Tpc44hSXO|YYm= MYGwMVEh|ryP M4\YVFI1yqCq M3zVc4lv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NW\QfHVEOjV4MUK5OFE>
ML-1 NYnVUWtpTnWwY4Tpc44hSXO|YYm= M4jHV|AuOSEQvF2= NH;kbWEzPMLiaB?= NInDO5FqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmjONlU3OTJ7NEG=
RPMI-8226vr10  M1fJe2Z2dmO2aX;uJGF{e2G7 NITkc5cxNTFizszN MWGyOOKhcA>? M4LoN4lv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXzmWY9IOjV4MUK5OFE>
ML-1 NUHNPXVXTnWwY4Tpc44hSXO|YYm= NV\DNGVkOSEQvF2= MXOyOOKhcA>? NYD6XmhNcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ> Ml\2NlU3OTJ7NEG=
RPMI-8226vr10  MXLGeY5kfGmxbjDBd5NigQ>? M3zufFEh|ryP NG\ZbokzPMLiaB?= MVzpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFIvPS2ob3zk M2PsO|I2PjF{OUSx
SK-N-BE (2) NVrEW|FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWyOQKBkWh? NWK1doV6UUN3ME2xNFQvOOLCidMx5qCKPy56IH7N NYrXO5lxOjV|MEi5NVY>
SK-N-BE (2), PAN  MK MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[yOQKBkWh? MVjJR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? MYSyOVMxQDlzNh?=
SK-N-BE (2), MK  PAN NFv6eVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVflXnhnOjUkgJno MnvhTWM2OD1|OEKuNQKBkcLz4pEJOFMvOiCwTR?= NHPF[FQzPTNyOEmxOi=>
SK-N-AS MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK1Vm4zPOLCiXi= NXr2e2JOUUN3ME2zO{4y6oDLwsJihKkzNjRibl2= M33UR|I2OzB6OUG2
SK-N-DZ NVLqXWNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOyOQKBkWh? M3rQNGlEPTB;MUeuNgKBkcLz4pEJNE41KG6P M{jhNVI2OzB6OUG2
Caki-1 NH3zb2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfrNVAwOjVxNUCgcm0> NGnaSpY1QCCq MmTGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MWCyOVI4QTF7MR?=
ACHN M{e2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzvenAyOC9{NT:1NEBvVQ>? NXTqT25{PDhiaB?= MkLpbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ NEO5cGwzPTJ5OUG5NS=>
769-P Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzkN2xmOTBxMkWvOVAhdk1? MmjQOFghcA>? NFzicmlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MYCyOVI4QTF7MR?=
786-O  NFWxT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTYOZV5OTBxMkWvOVAhdk1? MlPMOFghcA>? M4nuSolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= M{L5S|I2Ojd7MUmx
Caki-1 MnW5RZBweHSxc3nzJGF{e2G7 NWPSNVh2PTBibl2= NHLENIY1QCCq MnjxbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? NEXFOFczPTJ5OUG5NS=>
ACHN MkO3RZBweHSxc3nzJGF{e2G7 M3rzSFUxKG6P MX20PEBp MnXVbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? MnfkNlUzPzlzOUG=
769-P MmK3RZBweHSxc3nzJGF{e2G7 NGLGdpk2OCCwTR?= NFzKb5U1QCCq NFXyV2dqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= MXWyOVI4QTF7MR?=
786-O  MYfBdI9xfG:|aYOgRZN{[Xl? MVm1NEBvVQ>? NEDMWlQ1QCCq NW\MOm9JcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= NX[3bZJ4OjV{N{mxPVE>
Caki-1 MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PBblI2NzVyIH7N NFfKZ3M1QCCq NWHUT4xDTE2VTx?= M2Ha[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= M1;SS|I2OTd4M{W0
ACHN NH7Ye|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmqxNlUwPTBibl2= MXq0PEBp NUP3ZZpSTE2VTx?= MmDhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= MoTTNlUyPzZ|NUS=
769-P NWT2UFB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXCNlUwPTBibl2= MYW0PEBp NUjNR2VETE2VTx?= Ml6zbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= M1PtSVI2OTd4M{W0
Caki-1 NXvUNYJbS2:ub375JGZwem2jdHnvckBCe3OjeR?= M4jvWVUxKG6P MY[3MVE1KGR? NHmxZpVFVVOR M{S4XZN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh M33nUVI2OTd4M{W0
ACHN NEHqTIJEd2yxbomgSo9zdWG2aX;uJGF{e2G7 M4C5OVUxKG6P MUe3MVE1KGR? NHPpbnJFVVOR MWrzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> M2DF[|I2OTd4M{W0
769-P Mn3JR49td267IF\vdo1ifGmxbjDBd5NigQ>? MXS1NEBvVQ>? MmXqO{0yPCCm MVjEUXNQ NHKwVXV{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? MV2yOVE4PjN3NB?=
Caki-1 NY\lPGZ3SXCxcITvd4l{KEG|c3H5 MXW1NEBvVQ>? NIHTRpc1QCCq NUDySZhpTE2VTx?= MXfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3\iSFI2OTd4M{W0
ACHN MmfGRZBweHSxc3nzJGF{e2G7 NEjDNnE2OCCwTR?= MkW2OFghcA>? NFHuUGlFVVOR MYHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVGyOVE4PjN3NB?=
769-P Mmj3RZBweHSxc3nzJGF{e2G7 MnLsOVAhdk1? MYK0PEBp NWWyTW5UTE2VTx?= NYT6WG1ScW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4PSNFI2OTd4M{W0
MDA-MB-231 M33W[m1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? MVOxNOKhdk1? MojXN:Kh\A>? M4\lN2ROW09? MlrTZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NWK3OmxtOjR6MUC0PVc>
BT-549 NUnudno{VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MXuxNOKhdk1? Mo\iN:Kh\A>? MV\EUXNQ M3:4VYFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= NHzh[Y0zPDhzMES5Oy=>
MCF-7  NWHzdJU{VW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MWOxNOKhdk1? MUGzxsBl NFP0WWZFVVOR MnT2ZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NHL0VIwzPDhzMES5Oy=>
MCF-7 Ml3zSpVv[3Srb36gRZN{[Xl? M1PHVFUuPTBibl2= NFfkU|kzPCCq MULEUXNQ M2rKZ5Jm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> MUSyOFM3PjRyNx?=
CTS M{DneGFxd3C2b4Ppd{BCe3OjeR?= NV3yUppOOOLCk{SwJI5OyqB? MlnDOFghcA>? MlvabY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3fWNFI1OjR2NEK5
OCI-AML3  NWq1NpNTSXCxcITvd4l{KEG|c3H5 M1v4blDjiJN2MDDuUeKh M3\Wd|Q5KGh? NYfyTHdXcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MUCyOFI1PDR{OR?=
U937 MnXrRZBweHSxc3nzJGF{e2G7 M4eyV|DjiJN2MDDuUeKh NXnpT5B7PDhiaB?= NVXJR4xMcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MUmyOFI1PDR{OR?=
PC3 M4e4RmFxd3C2b4Ppd{BCe3OjeR?= MkDUNE0yODBibl2= M1fDVVI1NzR6IHi= M2jyV4lv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2D4NlI1OTZ|MkOw
PC3-AR M3;yfWFxd3C2b4Ppd{BCe3OjeR?= MX2wMVExOCCwTR?= NFrFU2czPC92ODDo M{TsOolv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUPFUm9DOjRzNkOyN|A>
PC3 NHzScmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH2OFZ3OC1zMECgcm0> NUj5c2E5OjRxNEigbC=> MkXrbY5lfWOnczDhZ4N2dXWuYYTpc44hd2Zic4XiS|EheG:ydXzheIlwdg>? NEXCfo8zPDF4M{KzNC=>
PC3-AR NIHhZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn2S25iOC1zMECgcm0> NI\6OYUzPC92ODDo M{C5[Ylv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG|ZR?= MV[yOFE3OzJ|MB?=
PC3 NISzd3JHfW6ldHnvckBCe3OjeR?= NY\XbFVpOC1zMECgcm0> MkDVNlQhcA>? MoHwd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= NIr3UmgzPDF4M{KzNC=>
PC3-AR NXz2UFUyTnWwY4Tpc44hSXO|YYm= MUKwMVExOCCwTR?= M1PsVlI1KGh? NYn4U2xse3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> M3j5cFI1OTZ|MkOw
OS-RC-2 MljxR4VtdCCYaXHibYxqfHliQYPzZZk> NEfVc3ExNTFyMECgcm0> M3nufFI1NzR6L{eyJIg> M1W0SmROW09? NH;MRpVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz NYXxeXp1OjRzNES3N|c>
OS-RC-2 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn4OVAhdk1? MUC0PEBp M{fn[2ROW09? MXTpcoR2[2W|IFeyM20h[XK{ZYP0 Mlv5NlQyPDR5M{e=
OS-RC-2 MlfHRZBweHSxc3nzJGF{e2G7 MUG1NEBvVQ>? NVX4VYVvPDhiaB?= NGC3PY1FVVOR NYfaRoVscW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NEfj[2UzPDF2NEezOy=>
SK-N-AS M1v1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDB[mFQOOLCk{iwJI5O NXLTV4VqPDhiaB?= MXzJR|UxRTJ5LkSgcm0> Mkf5NlQxQTh5OUm=
SK-N-DZ M{PiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX4NQKBmzhyIH7N NWWyWYk3PDhiaB?= MoDzTWM2OD1{MT65JI5O NFzpc4ozPDB7OEe5PS=>
SK-N-SH NX;oNZdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\2PFluOOLCk{iwJI5O NFnOWok1QCCq NH7C[5NKSzVyPUeyMlMhdk1? MXyyOFA6QDd7OR?=
SK-N-BE NV:xNHc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\iNQKBmzhyIH7N M2DZSVQ5KGh? MWnJR|UxRTd3LkSgcm0> Ml\xNlQxQTh5OUm=
SK-N-AS NFvaOJFCeG:ydH;zbZMhSXO|YYm= NI\QRYkx6oDVOECgcm0> Mn[4OFghcA>? NXnwZZc4eG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v MXuyOFA6QDd7OR?=
SK-N-DZ M{HoR2Fxd3C2b4Ppd{BCe3OjeR?= MlvJNQKBmzhyIH7N NVHmflJrPDhiaB?= NXjITIozeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v M1TSVVI1ODl6N{m5
SK-N-SH NX[3c5JnSXCxcITvd4l{KEG|c3H5 MUGw5qCUPDBibl2= NFzMelg1QCCq NHjSUmlxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NX75XYI5OjRyOUi3PVk>
SK-N-BE M2\pXGFxd3C2b4Ppd{BCe3OjeR?= M3\6PVDjiJN2MDDuUS=> Mn3JOFghcA>? MoLxdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u Mnu5NlQxQTh5OUm=
SK-N-AS M4LYV2Z2dmO2aX;uJGF{e2G7 MUOw5qCUQDBibl2= NGrRWmM1QCCq NFuydJVqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR MlOzNlQxQTh5OUm=
SK-N-DZ MlPwSpVv[3Srb36gRZN{[Xl? NGHicGEx6oDVOECgcm0> MWO0PEBp MXLpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ NF;mbJIzPDB7OEe5PS=>
SK-N-SH NYLOSmZITnWwY4Tpc44hSXO|YYm= MYSw5qCUPDBibl2= MoHHOFghcA>? MVnpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ Ml\hNlQxQTh5OUm=
SK-N-BE Mk\JSpVv[3Srb36gRZN{[Xl? M2LmVFDjiJN2MDDuUS=> NF3LV|A1QCCq M{TmZYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NHj5PYszPDB7OEe5PS=>
HCC-LM3 M4WweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCzNU0yODByIH7N MlLLNlQwPDhxN{KgbC=> Mm\oSG1UVw>? NFj2clFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFrw[2UzPDB7M{m1Oi=>
HepG2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXXNU0yODByIH7N NUfzTIw1OjRxNEivO|IhcA>? MVXEUXNQ MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2HNV|I1ODl|OUW2
SMMC-7721 NYXsfXJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHDSGoyNTFyMECgcm0> M2Dqc|I1NzR6L{eyJIg> NGrafFFFVVOR NGDwe5pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NIfkXYwzPDB7M{m1Oi=>
HCC-LM3 NYLEUHlkSXCxcITvd4l{KEG|c3H5 M4PGW|UxKG6P Mk\JOFghcA>? NE\ZZWxFVVOR M1nr[Ylv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 NVPKTHlXOjRyOUO5OVY>
HepG2 M2izdmFxd3C2b4Ppd{BCe3OjeR?= NIPwZmo2OCCwTR?= NG\4R5c1QCCq NGH4d5JFVVOR MoPHbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> NUHSOGI{OjRyOUO5OVY>
SMMC-7721 M1:5UWFxd3C2b4Ppd{BCe3OjeR?= NX3UW4pOPTBibl2= Mn3aOFghcA>? NUfSXVlNTE2VTx?= NFqyfYNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? NIHxdHYzPDB7M{m1Oi=>
HCC-LM3 MYHGeY5kfGmxbjDBd5NigQ>? NF22doU2OC9zMECgcm0> NX\WOY9pOjRiaB?= MX;EUXNQ NEfuTVZl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg MYiyOFA6Ozl3Nh?=
HepG2 MlTQSpVv[3Srb36gRZN{[Xl? MU[1NE8yODBibl2= M2\ZUFI1KGh? M1O5NmROW09? Mn7i[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= NWWzSHROOjRyOUO5OVY>
SMMC-7721 NEfsZ3JHfW6ldHnvckBCe3OjeR?= NWS4XZNFPTBxMUCwJI5O MmTqNlQhcA>? NFXqc|dFVVOR NVu4T4ZK\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> MUKyOFA6Ozl3Nh?=
HCC-LM3 NXvvNY1FTnWwY4Tpc44hSXO|YYm= M3v3Z|UxNzFyMDDuUS=> M{m3blI1KGh? MUDEUXNQ Mo\D[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? NXPHfHVpOjRyOUO5OVY>
HepG2 M1j3WWZ2dmO2aX;uJGF{e2G7 NEnoPWQ2OC9zMECgcm0> NYK2OIp5OjRiaB?= M2T3NGROW09? MoLp[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? MnPHNlQxQTN7NU[=
SMMC-7721 MYjGeY5kfGmxbjDBd5NigQ>? NVnTV2J7PTBxMUCwJI5O NFT0[40zPCCq MoW3SG1UVw>? NIK2THFld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w NXPtdpBKOjRyOUO5OVY>
FaDu M320RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfKPVlMOTBy4pEFcm0> NE\WemU5NzFyL{GyJIg> M2HpW4Rqe3CuYYnl[EBiKHOrZ37p[olk[W62IHHu[EBxem:ub37n[YQhTzJxTTDhdpJme3RiYYSgPEBidmRiMUNihKVpKHCxc4SgdoVt\WG|ZR?= NUKzbGVrOjRyMk[0PFI>
FaDu NGDYOXpHfW6ldHnvckBCe3OjeR?= MXuxNFDjiIWwTR?= MV6yM|QwQC9zMjDo MnjZbY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25? NGnF[ZAzPDB{NkS4Ni=>
PC-3  NXv2RWZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILyXWQxNTFyIN88US=> NFjNNHIzPC92OD:3NkBp NHPCdYNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGD5PXYzOzl7MUKxOi=>
LNCaP MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\KPFloOC13IN88US=> NFzNSYgzPC92OD:3NkBp NEHSNoVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NF\sXnIzOzl7MUKxOi=>
RWPE-1  Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj6dHQxNTJyIN88US=> MkTVNlQwPDhxN{KgbC=> MljHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIS5UJkzOzl7MUKxOi=>
Capan-1 NHPCOIRHfW6ldHnvckBCe3OjeR?= MVuyOU82OC9zMECgcm0> MYm4M|I1NzR6IHi= M{H5bWROW09? NEfQR|Jld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n NGTiV|IzOzl{Mki4Oi=>
L3.6pl NF3Hd3BHfW6ldHnvckBCe3OjeR?= M1flSVI2NzVyL{GwNEBvVQ>? NHXGVY45NzJ2L{S4JIg> M{SzO2ROW09? NXj3Zmlv\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> NEfOfIUzOzl{Mki4Oi=>
CFPAC-1  NHS3Xm1HfW6ldHnvckBCe3OjeR?= NX\mWlRDOjVxNUCvNVAxKG6P NXHRNVFlQC9{ND:0PEBp NF[wUmNFVVOR Mon3[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?= MUiyN|kzOjh6Nh?=
Capan-1 M3Tmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vOb|I2NzVyL{GwNEBvVQ>? MXO0PEBp M2nmbmROW09? M1HEbZJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlzVNlM6OjJ6OE[=
L3.6pl NUjlVnRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SzN|I2NzVyL{GwNEBvVQ>? MlL1OFghcA>? M3fZUWROW09? NX\hepBVemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4j5fVI{QTJ{OEi2
CFPAC-1  MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDhVnQ5OjVxNUCvNVAxKG6P NXG2[21WPDhiaB?= M3fkSmROW09? NWTTbpExemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mk\yNlM6OjJ6OE[=
Capan-1 MYnBdI9xfG:|aYOgRZN{[Xl? NFLqNXQzPS93MD:xNFAhdk1? Mm[5OFghcA>? MUnEUXNQ NVjndZpFcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHvZe5ozOzl{Mki4Oi=>
L3.6pl MXPBdI9xfG:|aYOgRZN{[Xl? MXSyOU82OC9zMECgcm0> MYq0PEBp M2T0TmROW09? MkOybY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWH4bXhMOjN7MkK4PFY>
CFPAC-1  MYfBdI9xfG:|aYOgRZN{[Xl? M1\BVVI2NzVyL{GwNEBvVQ>? NHy1VJA1QCCq MVzEUXNQ NFKyXWdqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYSyN|kzOjh6Nh?=
HN22 NXnETI9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LkeFAuOjBibl2= NXHWS21POjRxNEigbC=> NEfXXWFFVVOR MWHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy MVmyN|g4PzJ|NR?=
HSC4  MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYewMVIxKG6P MYOyOE81QCCq Ml6wSG1UVw>? NWTCd5MxcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? M3G2dVI{QDd5MkO1
HN22 NYTjOoJkSXCxcITvd4l{KEG|c3H5 MnrQNE0zOCCwTR?= NHy3U241QCCq MWjEUXNQ MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NUm1WXpkOjN6N{eyN|U>
HSC4  MXnBdI9xfG:|aYOgRZN{[Xl? NYPHcYFqOC1{MDDuUS=> NVv6cmdLPDhiaB?= MVXEUXNQ MlrIbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M{HXc|I{QDd5MkO1
HN22 NHnFVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrFNE0zOCCwTR?= NUXnWpA3PDhiaB?= MYTEUXNQ NXvl[5U{cW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh NHzKSGwzOzh5N{KzOS=>
HSC4  Mnq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonVNE0zOCCwTR?= M{jjNVQ5KGh? MoPaSG1UVw>? NUnj[mQ3cW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh MljHNlM5Pzd{M{W=
HN22 MWDGeY5kfGmxbjDBd5NigQ>? NYLCR25wOC1{MDDuUS=> MVq0PEBp NWLMSJI5TE2VTx?= NULrUo9xe3WycILld5NmeyCVcEGg[ZhxemW|c3nvcuKh NF7TfGEzOzh5N{KzOS=>
HSC4  NXH3NmZlTnWwY4Tpc44hSXO|YYm= NYrqO5BvOC1{MDDuUS=> NXvCTnd7PDhiaB?= MWTEUXNQ NVjMdmx1e3WycILld5NmeyCVcEGg[ZhxemW|c3nvcuKh M4TOOVI{QDd5MkO1
Cal62 MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTN|INMxJFQhdk1? M2rtUFI{QDJ2ME[0
Hth7 NUnMR5MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;aTWM2OD1zNTFCtUAzKG6P Ml64NlM5OjRyNkS=
Hth83 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfqd5VKSzVyPUO0JOKyKDVibl2= MmnWNlM5OjRyNkS=
C643 M13veGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXHTWM2OD15MTFCtUAyOCCwTR?= MoTvNlM5OjRyNkS=
SW1736 NIThb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTOTWM2OD1|NTFCtUA5KG6P NITScJUzOzh{NEC2OC=>
T241 M{DmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTKTWM2OD14NTFCtUA4KG6P M1m3TlI{QDJ2ME[0
T351 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTVyINMxJFExKG6P NEHod4IzOzh{NEC2OC=>
BHP2-7 NEnCVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzNU4pHUUN3ME2zO{DDuSB4IH7N MVuyN|gzPDB4NB?=
T238 NH\CbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknlTWM2OD1zLEWwNEDDuSB{MECgcm0> NVrDb2prOjN6MkSwOlQ>
HCT8 M4XsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[w[VBxPzJiaB?= NFjGUVJFVVOR NHHv[YFKSzVyPUGyMlnjiIoEsfMAjVEvQSCwTR?= M4ntOVI{Ojl7M{i4
H630 M3z5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe3NkBp NYe5TpduTE2VTx?= M4Xzd2lEPTB;MUKuOQKBkcLz4pEJN{4yKG6P MUWyN|I6QTN6OB?=
cH630 5-FU-res NHTaT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\aN4V3PzJiaB?= NWjycJhsTE2VTx?= NETkc5RKSzVyPUG1MlXjiIoEsfMAjVEvOiCwTR?= MkHYNlMzQTl|OEi=
HCT116 M4jqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnIPHI2PzJiaB?= NVGyNVNqTE2VTx?= MUnJR|UxRTFyLkhihKnDueLCiUKuNkBvVQ>? MlnuNlMzQTl|OEi=
HCT116 p53−/− MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITWWlc4OiCq MV7EUXNQ NYHsbGhnUUN3ME24MlbjiIoEsfMAjVEvPyCwTR?= NXq4enR5OjN{OUmzPFg>
dHCT116 p21−/− MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[wUlczKGh? NImzdoxFVVOR MlLOTWM2OD13LkpihKnDueLCiUGuN{BvVQ>? MXGyN|I6QTN6OB?=
HT29 Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPERlBGPzJiaB?= MknkSG1UVw>? M{L1NGlEPTB;MU[uN-KBkcLz4pEJNk4{KG6P MVGyN|I6QTN6OB?=
LoVo Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XjcVczKGh? NY[5WmxSTE2VTx?= M4XHZWlEPTB;NT6x5qCKyrIkgJmwMlYhdk1? NGHqOFEzOzJ7OUO4PC=>
RKO NFvseI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DqNlczKGh? MXjEUXNQ NGnROFhKSzVyPUeuPgKBkcLz4pEJNk4zKG6P NEnhcJUzOzJ7OUO4PC=>
SW480 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXO1VIpTPzJiaB?= M2DIdGROW09? NHXP[pVKSzVyPUG3MlXjiIoEsfMAjVAvQCCwTR?= M2LUfFI{Ojl7M{i4
eSW620 NEnybpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13MPVczKGh? MW\EUXNQ NIHKV5ZKSzVyPUmuNgKBkcLz4pEJNk4yKG6P M2n4N|I{Ojl7M{i4

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
体内研究 LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长,与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多,说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射,每周持续5天,导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比,LBH589作用于H526衍生的肿瘤下降53%,作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%,作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下,LBH589 作用于NSCLC和Meso衍生的移植瘤,导致SCLC衍生的肿瘤中有两种衰退,伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm3降低到实验结束时的116 mm3,RG-1衍生的平均肿瘤尺寸从实验开始时的185mm3降低到实验结束时的86 mm3[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: MOLT-4细胞和Reh(前体B细胞)
  • Concentrations: 50 nM
  • Incubation Time: 48小时
  • Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色,然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×104个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比,根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 携带10×106个M30细胞或5×106个A549细胞的SCID鼠
  • Formulation: 溶于水的5%葡萄糖
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 349.43
化学式

C21H23N3O2

CAS号 404950-80-7
储存条件 粉状
溶于溶剂
别名 NVP-LBH589

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT03515915 Recruiting -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo mice study?

  • 回答:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Panobinostat (LBH589) | Panobinostat (LBH589)供应商 | 采购Panobinostat (LBH589) | Panobinostat (LBH589)价格 | Panobinostat (LBH589)生产 | 订购Panobinostat (LBH589) | Panobinostat (LBH589)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID